CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for DongKoo Bio & Pharma Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

DongKoo Bio & Pharma Co Ltd
195-2, Gocheok 2-dong, Guro-gu
Phone: +82 226845421p:+82 226845421 SEOUL, 05854  South Korea Ticker: 006620006620
Business Summary
Dongkoo Bio&Pharma Co.,Ltd. is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The major products include antihistamines, topical steroids, therapeutic agents for prostatitis, treatments for benign prostatic hyperplasia, atherosclerotic agents, and antibiotics, among others. The Company is involved in contract manufacturing organization business. It manufactures and sells therapeutic for osteoporosis, antiviral agents, erectile dysfunction treatments, hepatic disease agents; painkillers; gum treatments. In addition, the Company is engaged in the manufacturing and sale of medical devices and cosmetics. The Company distributes its products within the domestic market and to overseas markets, including America and Europe.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
6799 Investors, not elsewhere classified
6159 Miscellaneous business credit institutions
7319 Advertising, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Operating Officer, Director Jae HongPark 61
Chief Executive Officer, Director Yong JunCho 57
Vice President, Director Jong MunKim 59
8 additional Officers and Directors records available in full report.

General Information
Number of Employees: 402 (As of 12/31/2023)
Outstanding Shares: 27,623,549 (As of 12/31/2023)
Shareholders: 18,128
Stock Exchange: KDQ
Fax Number: +82 226811880


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 28, 2024